Accuray (NASDAQ:ARAY) posted its quarterly earnings data on Tuesday. The medical equipment provider reported ($0.01) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.03, Fidelity Earnings reports. Accuray had a negative net margin of 3.85% and a negative return on equity of 25.96%. The business had revenue of $103.22 million for the quarter, compared to analysts’ expectations of $104.02 million. Accuray updated its FY 2019 guidance to EPS.

NASDAQ ARAY opened at $4.24 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.71 and a debt-to-equity ratio of 2.97. Accuray has a 12 month low of $3.16 and a 12 month high of $5.40.

In other news, CEO Joshua Levine sold 6,604 shares of the company’s stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $4.54, for a total value of $29,982.16. Following the transaction, the chief executive officer now directly owns 1,033,593 shares in the company, valued at $4,692,512.22. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 3.40% of the company’s stock.

A hedge fund recently raised its stake in Accuray stock. Geode Capital Management LLC lifted its stake in Accuray Incorporated (NASDAQ:ARAY) by 14.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 992,090 shares of the medical equipment provider’s stock after purchasing an additional 126,656 shares during the period. Geode Capital Management LLC owned about 1.13% of Accuray worth $3,382,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 80.19% of the company’s stock.

A number of research analysts have recently commented on ARAY shares. Zacks Investment Research upgraded shares of Accuray from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a report on Thursday, February 7th. BidaskClub upgraded shares of Accuray from a “strong sell” rating to a “sell” rating in a report on Thursday, January 10th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $5.13.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at

About Accuray

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.

Featured Article: Certificate of Deposit (CD)

Earnings History for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with's FREE daily email newsletter.